Abbott Laboratories has reported sales of $10.6bn for the third quarter (Q3) of 2024, as against $10.4bn in Q2 2024, with ...

There are many reasons to own Abbott Laboratories (NYSE: ABT), but they all boil down to one thing: consistent market-beating returns.

Abbott Laboratories ABT reported better-than-expected third-quarter results on Wednesday. The company posted sales of $10.64 ...

Q3 2024 Earnings Call Transcript October 16, 2024 Abbott Laboratories beats earnings expectations. Reported EPS is $1.21, ...

TD Cowen analyst Josh Jennings maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) today and set a price target ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, ...

On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating ...

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

Wall Street trading got off to a mixed start on Wednesday as the Dow Jones tried to claw back some of the heavy losses ...

Morgan Stanley (NYSE:MS) stock rose 4% after the lender's profit surpassed estimates on a bumper third quarter for investment ...

Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...